Medpace is home to renowned regulatory and therapeutic experts who are committed
to the complex and intertwined therapeutic areas of cardiology.
With extensive experience in Phase I-IV research, our team of international therapeutic
leaders have dedicated their careers to bringing drugs to market that treat or prevent
heart disease. In fact, they have helped pioneer many of the preventative cardiovascular
compounds introduced in the last 15 years.
Medpace regulatory experts are former government officials who have invaluable insight
into the specific area of cardiovascular drug and medical device approval. They are an integral part
of every study and their valuable guidance ensures every step efficiently accelerates
the approval process.
Medpace experience in large cardiovascular endpoint trials
The Medpace ability to integrate cardiovascular trials with metabolic/endocrinology projects across both therapeutic and regulatory knowledge bases provides sponsors with unique capabilities for large studies demanding rigorous safety requirements. Electronic endpoint adjudication capabilities coupled with strategic consultation and management of all outcomes and regulatory requirements, keeps projects on track.
- Acute coronary syndrome
- Coronary artery disease
- Heart failure
- STEMI and non-STEMI
>> Click here to learn more
about Medpace's capabilities and therapeutic expertise in cardiology.